Acute generalized exanthematous pustulosis (AGEP) is a rare drug-induced pustular cutaneous reaction. The clinical course is characteristic with a sudden onset of multiple sterile pustules on an erythemantous base with fever and neutrophilia, followed by a spontaneous resolution within two weeks. Drug-specific T cells play the main role in the pathogenesis, but the exact cytokine cascade and genetic background are yet to be elucidated. Timely and exact recognition is important in order to prevent confusion with infections and psoriasis and hence institution of unnecessary and wrong treatments. The diagnosis may be confirmed by typical history, identification of a culprit drug, histopathology and patch testing. The purpose of this review is to present the current knowledge on AGEP and its association with various drugs in the context of a drug allergic reaction.
INTRODUCTION
AGEP is a rare self-limiting pustular cutaneous reaction, most commonly triggered by intake of certain drugs. Its characteristic clinical findings with acute development of pustular rash and fever along with a typical histology allow for a timely diagnosis and proper management.
The term acute generalized exanthematous pustulosis was first compiled by Beylot et al. in 1980 (1) . This name is now widely used for this characteristic reaction pattern, although the disease has been given numerous other labels in the medical literature such as toxic pustuloderma, pustular drug rash and pustular psoriasiform eruption with leucocytosis (2) .
Epidemiology The estimated incidence of AGEP ranges from one to five cases per million people per year (3). The actual incidence is most probably higher taking into account the reporting under different names in the literature, the low level of spontaneous drug reactions reporting and the transient nature of the disease. Any age could be affected and childhood occurrence has also been described (4,5). Female predisposition has recently been suggested (3,6) and this trend is consistent with the general trend for female predominance in drug reactions (7). Seasonality has also been reported in one study with a case series of patients developing the disease during the summer months (3).
Pathogenesis AGEP is a drug-induced reaction mediated by drug-specific T-cells (CD4+ and CD8+) and interleukin (IL)-8. IL-8 is responsible for priming, i.e. activation and recruitment of neutrophils that initiate a neutrophil-mediated inflammatory reaction in the skin by drug-specific cytotoxicity and by release of inflammatory cytokines and chemoattractants such as IL-5, interferon-gamma (IFN-γ), granulocyte-macrophage colony-stimulating factor (GM-CSF), transforming growth factor (TGF-β) and RANTES (8).
Drug-specific CD4(+) and CD8(+) T cells are both cytotoxic and activated to secrete cytokines. T cells produce perforin/granzyme B and activate the Fas/FasL-killing mechanism thus allowing the formation of vesicles. IL8-producing T-cells from AGEP patients are predominantly Th1-type and secrete both factors that attract neutrophils and factors that reduce and impede neutrophil apoptosis. Additional secretion of IL-8 by T cells and keratinocytes attracts neutrophils that fill the vesicles and transform them into the sterile pustules of AGEP (9) (10) (11).
Most recent studies suggest a possible involvement of keratynocytic IL-8 and drug-activated Th17 cells in the pathogenesis of AGEP. Both Th17 cells and their main product -IL-22 are found to be elevated in patients with AGEP compared to healthy controls. The authors speculate that IL-17 and IL-22 stimulate keratynocytes to produce IL-8 thus inducing the formation of the subcorneal infiltrate of neutrophils that is a hallmark of AGEP (12).
Genetic predisposition is also believed to be a background for reaction triggering and neutrophil shifting but data is still insufficient to postulate a pathogenetic role. Bernhard et al. found an enhanced expression of HLA B51, DR11 and DQ3 in patients with AGEP compared to the average population (13).
Causes and risk factors AGEP has been attributed to a variety of causes, but so far drugs seem to be the main culprit.
Drugs Enormous number of medications has been reported in the medical literature to cause AGEP, both in individual cases and small series. Nevertheless, causative drugs for AGEP differ substantially from drugs associated with Stevens Johnson syndrome/ toxic epidermal necrolysis (SJS/TEN) or other skin drug reactions.
The EuroSCAR study (a multinational casecontrol study, including 97 patients with AGEP) evaluated the risk for different drugs to cause severe cutaneous drug reaction and revealed agents with strong and agents with weak association to the disease. As drugs with high risk to trigger AGEP were defined pristinamycin, ampicillin/amoxicillin, quinolones, (hydroxy)chloroquine, sulphonamides, terbinafine and diltiazem. Less strong association was recorded for corticosteroids, macrolides, non-steroidal anti-inflammatory drugs of the oxicam type and antiepileptics (excluding valproic acid) (2 Time of onset after drug intake is variable and it is suggested to be related to the specific drug and its mechanism of reaction induction. While most drugs require a latent time of 1-2 weeks before AGEP presents clinically, some other drugs, such as pristinamycin and amoxicillin could induce a reaction after only one day of intake. The rapid onset might be due to a re-challenge after previous exposition to the culprit drug or to another mechanism that has so far not been elucidated (2) . Longer latent periods have been reported in the literature in association with an underlying malignancy (19) (20).
Infections Stringent evidence that infections cause AGEP are lacking, even though there are case reports associating AGEP with viral infections, including infections with Parvovirus B19 (29), Cytomegalovirus (30), Coxsackie B4 virus (31). Recurrent urinary tract infections (32) and Chlamydia pneumoniae (33) have also been reported as causative factors for AGEP. Nevertheless, the EuroSCAR study did not find any significant risk for infection in a multivariate analysis including all 97 validated AGEP cases and 1009 controls (2) . These findings strongly suggest that the suspected association of infections with AGEP might be due to the anti-infective treatment prescribed to treat the disease and not to the very infection.
Psoriasis Differential diagnosis between AGEP and pustular psoriasis (PP) is difficult. The clinical and histological presentation, as well as the Ki-67 expression (34) of both entities are similar which renders into confusion about their differentiation and overlap. Although several cases of AGEP occurred in patients with personal or family history of psoriasis, current evidence suggests that there is no significant difference in relation to psoriasis history between AGEP patients and healthy controls (2) . The slightly high-er incidence in the AGEP group could be due to a common genetic background that favours neutrophil-attracting mechanism in response to triggering drugs. Furthermore, many drugs known to exacerbate or trigger psoriasis (eg. beta-blockers or angiotensin converting enzyme (ACE) inhibitors) have not been associated with AGEP.
Other factors Contact sensitivity. Few cases suggest a role of topical agents to induce AGEP through contact sensitivity. Bufexamac, a topical NSAID, induced AGEP in an atopic girl and its role was evidenced by a positive withdrawal and a positive patch test (35). A mephenesin-containing topical treatment for muscular pain was reported as a causal factor for AGEP in a 51-year old patient and the sensitivity was further confirmed with a positive patch testing (36).
Spider bites. Role of spider bites was suggested in a series of cases and case reports of patients that developed AGEP after being bitten by a spider (37). The underlying mechanism most probably includes a highly increased number of pro-inflammatory cytokines (IL-8 and GM-CSF) by the spider venom with subsequent systemic reactions.
It was recently suggested that AGEP may develop without an apparent causal factor, albeit very rarely (38). Indeed, in a series of 63 cases three patients remained without an elucidated trigger (39). Hence, it is very important to still consider the diagnosis when presenting with typical clinical and laboratory findings, even when a causative factor could not be identified.
Clinical presentation
The clinical features and clinical course of AGEP are characteristic and usually sufficient for an initial diagnosis.
AGEP presents with the acute occurrence of oedematous erythema covered by dozens to hundreds of pinhead, non-follicular, sterile pustules ( Figure  1) . The rash has a predilection for the main folds, but widespread distribution is common. Less often AGEP could manifest with atypical type of lesions including face oedema, purpura, blisters or targetoid lesions (39) (40). Involvement of mucous membranes is uncommon, usually mild and restricted to one body site (most commonly the oral cavity). Systemic symptoms almost always accompany the cutaneous manifestations and comprise of fever (above 38%) and leucocytosis with a neutrophil count of more than 7000/µl. Mild eosinophilia has been detected in about one third of patients (39,41).
The clinical course of AGEP is a characteristic feature of the disease. Skin symptoms have a sudden onset and spontaneous quick resolution. The pustules resolve with a pinpoint desquamation followed by a total clearance within several days. Usually the episode lasts for up to 15 days when exposure to the trigger is discontinued (39,40). Repeated exposure to the causative drug results in a recurrence of the disease (42).
The prognosis is favourable and complications are very rare, mostly affecting patients with other serious comorbidities. Few case reports of internal organ involvement have raised the hypothesis that AGEP might be a multi-system disorder (43,44,45) but accumulated epidemiologic data does not support such conclusions. Mortality has been reported to be 5% (3).
WORK UP AND LABORATORY FINDINGS
Histopathology Pustules, sub/intracorneal, intraepidermal or a combination of both are found in more than 90% of the cases. Although the rash is primarily not follicular, in almost one quarter of all patients the pustules show follicular distribution. The main epidermal features are necrotic keratinocytes and spongiosis with neutrophil exocytosis. The main dermal features are papillary oedema, mixed superficial, interstitial and mid/deep-dermal infiltrates containing neutrophils and eosinophils (Figure 2 ). Characteristic features of classical plaque-type psoriasis are infrequent and mild. Parakeratosis is the only finding that can be observed in more than half of cases, but Munro abscesses, suprapapillary plate thinning, tortuous and dilated blood vessels and hypogranulosis are rare (41).
Patch testing
Numerous case reports of AGEP include strongly positive reactions to the culprit drug when patients are patch tested. As a type IV, T-cell mediated hypersensitivity reaction, AGEP is suitable for patch testing as, when in contact with skin, drugs are likely to elicit a local T-cell response. Drug-specific T cells (CD4+ and CD8+) have been isolated and cultured from positively reacting patch test sites from patients with AGEP (9,46). Nevertheless, results are not invariably positive and the limited yield is probably due to several factors such as patch test methodology, skin barrier function, genetic factors of drug metabolism, drug molecular weight and solubility (47). The drugs with the highest frequencies of positive patch tests include aromatic anticonvulsants (carbamazepine and phenytoin), beta-lactams (especially amoxycillin) and amino-penicillins, co-trimoxazole, corticosteroids, diltiazem, diazepam, tetrazepam and pristinamycin (47). Most of these drugs are etiological triggers of AGEP which explains the relatively high percentage of patch test evidenced AGEP cases as compared to other drug eruptions.
Patch testing is so far the only routine test to examine a casual relation of AGEP to a suspected drug. It is safe and well tolerated and there is only one report in the literature so far about a generalized AGEP-like reaction following patch testing (48).
Differential diagnosis Pustular psoriasis is the entity that most closely resembles AGEP and there are still no clear-cut rules for differentiation of both diseases, though a set of different factors might be used.
Other differential diagnoses to consider include subcorneal pustular dermatosis, pustular vasculitis, drug hypersensitivity syndrome and Stevens Johnson syndrome/toxic epidermal necrolysis.
Treatment options
As AGEP has a self-limiting nature, most cases do not require management other than withdrawal of the culprit drug and supportive care. Systemic corticosteroid treatment has been advocated by some authors (49) but the potential of corticosteroids to cause AGEP must be born in mind. Systemic antipyretics might be considered given they are not suspected as a cause for the occurrence of AGEP.
Several treatments such as etanercept (50) and infliximab (51) have been tried in individual cases. TNF-alpha stimulates the inflammation and the p53-related apoptosis in AGEP, hence theoretically TNF-alpha inhibitors may offer and effective and fast treatment. Nevertheless, clinical experience with these agents is still scarce and their role in the treatment scheme of AGEP remains to be elucidated.
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